Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story

Anca Pantea Stoian; Doina Catrinoiu; Manfredi Rizzo; Antonio Ceriello

doi:10.1002/dmrr.3379

Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story

Diabetes Metab Res Rev. 2021 Feb;37(2):e3379. doi: 10.1002/dmrr.3379. Epub 2020 Jul 20.

Authors

Anca Pantea Stoian¹, Doina Catrinoiu², Manfredi Rizzo^{3

4}, Antonio Ceriello⁵

Affiliations

¹ Diabetes, Nutrition and Metabolic Diseases Department, "Carol Davila" University of Medicine, Bucharest, Romania.
² Faculty of Medicine, Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Ovidius University of Constanta, Constanta, Romania.
³ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Columbia, South Carolina, USA.
⁴ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
⁵ IRCCS MultiMedica, Milan, Italy.

Abstract

Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.

MeSH terms

Blood Glucose / drug effects*
Blood Glucose / metabolism
COVID-19 / blood
COVID-19 / epidemiology
COVID-19 / pathology
COVID-19 Drug Treatment*
Diabetes Complications / drug therapy
Diabetes Complications / epidemiology
Diabetes Mellitus / blood
Diabetes Mellitus / drug therapy*
Diabetes Mellitus / epidemiology
Glycemic Control / methods
Humans
Hydroxychloroquine / therapeutic use*
Hypoglycemic Agents / therapeutic use
SARS-CoV-2 / drug effects
Severity of Illness Index
Signal Transduction / drug effects

Substances

Blood Glucose
Hypoglycemic Agents
Hydroxychloroquine